This is a multinational non-interventional study based on newly collected data to assess demographics, disease, and treatment pattern of patients with chronic Heart Failure (HF) in a two-cohort design: one cohort will receive first prescription of empagliflozin as routine therapy for HF, the other cohort will receive HF therapy with drugs with another mechanism of action. Treatment of HF according to routine practice is determined by the physician independent of the participation of the patient in this non-interventional study.

Inclusion Criteria:

• Written informed consent prior to study participation
• Male and female patients ≥ 18 years at Visit 1
• Patients must be contractually capable and mentally able to understand and follow the instructions of the study personnel
• Patients with diagnosis of chronic heart failure NYHA Class 2-4
• Treatment-naïve for SGLT2i at visit 1
• Women of childbearing potential must take appropriate precautions against getting pregnant according to approval of chosen HF drug(s)

Exclusion Criteria:

• Missing physician's diagnosis of chronic heart failure
• Patients hospitalized at visit 1
• Life expectancy ≤ 12 months according to physician's assessment
• Lack of informed consent
• Pregnant or lactating females
• Participation in a parallel interventional clinical trial
• Chosen treatment with another SGLT2i drug than empagliflozin
• Having been enrolled into the non-empagliflozin-arm of this non-interventional study
• Current or prior treatment with SGLT2i at visit 1
• Patients with contraindications according to current Summary of Product Characteristics (SmPC)
• Patients with dependency or relationship to the treating physician

Patients with chronic Heart Failure (HF) in a two cohort design: one cohort will receive first prescription of empagliflozin as routine therapy for HF, the other cohort will receive HF therapy with drugs with another mechanism of action.

Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement".

Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

After structured results have been posted, all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.

For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.